Halozyme Therapeutics (HALO) : Zacks Investment Research ranks Halozyme Therapeutics (HALO) as 3, which is a Hold recommendation. 3 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. Not everyone is convinced about the stocks future, hence, the stock receives 1 Sell recommendation. The average broker rating of 4 research analysts is 1.75, which indicates as a Buy.
Halozyme Therapeutics (HALO) : The highest level Halozyme Therapeutics (HALO) is projected to reach is $16 for the short term and the lowest estimate is at $7. The consolidated price target from 3 rating analysts who initiate coverage on the stock is $12.58 and the possibility the share price can swing is $5.08.
Shares of Halozyme Therapeutics, Inc. rose by 1.41% in the last five trading days and 8.72% for the last 4 weeks. Halozyme Therapeutics, Inc. is up 4.12% in the last 3-month period. Year-to-Date the stock performance stands at -41.72%. Halozyme Therapeutics (NASDAQ:HALO): On Tuesdays trading session , Opening price of the stock was $10.36 with an intraday high of $10.38. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $10. However, the stock managed to close at $10.1, a loss of 1.94% for the day. On the previous day, the stock had closed at $10.3. The total traded volume of the day was 1,113,590 shares.
Halozyme Therapeutics, Inc. is a biotechnology company, which is focused on developing and commercializing oncology therapies that target the tumor microenvironment. The Companys development pipeline consists primarily of clinical-stage product candidates in oncology and diabetes. The product candidates in its pipeline are based on rHuPH20, a human recombinant hyaluronidase enzyme. rHuPH20 temporarily breaks down hyaluronic acid (HA). Its lead oncology program is PEGPH20 (PEGylated recombinant human hyaluronidase), a new molecular entity, under development for the systemic treatment of tumors that accumulate HA. The Company is in collaboration with pharmaceutical companies including, Roche, Pfizer, Janssen and Baxter for its drug delivery platform, ENHANZE, which enables biologics and small molecule compounds that are administered intravenously to be delivered subcutaneously.